South Australian Medicines Evaluation Panel (SAMEP)

The South Australian Medicines Evaluation Panel (SAMEP) was established in 2011 as an expert standing committee of the South Australian Medicines Advisory Committee (SAMAC) to ensure that all public hospitals provide a consistent approach to the management of High Cost Medicines. The main role of SAMEP is to review the use of High Cost Medicines, for a list of medicines being reviewed or previously reviewed, see the High Cost Medicine reviews page. 

SAMEP were the winners of the 2014 SA Health Award "Excellence in Non-clinical Services"

Their role

The role of SAMEP includes:

  • Evaluating the safety, the clinical efficacy and cost-effectiveness of high cost medicines proposed for inclusion in the Statewide High Cost Medicines Formulary.
  • Initiating reviews to evaluate the safety and effectiveness of high cost medicines which are not registered for use within Australia for the purpose of providing guidance to local hospital drug committees with regards to consideration of individual patient use requests.
  • Making recommendations to SAMAC with regards to which high cost medicines should be made available in South Australian public hospitals and on the potential place in therapy of these medicines.
  • Facilitating the monitoring of high cost medicine use in South Australian public hospitals.

Meeting dates

SAMEP meet every two months to review high cost medicine formulary applications. Scheduled meetings for 2020 are:

  • 29 January
  • 18 March
  • 13 May
  • 8 July
  • 9 September
  • 11 November


Chaired by Associate Professor Catherine Hill, SAMEP includes specialist clinicians, pharmacists, health economists, an ethicist and a consumer representative.

Name Expertise
Professor Catherine Hill, Chair Staff Specialist Rheumatology Unit, The Queen Elizabeth and Royal Adelaide Hospitals
Dr Damian Clark Paediatric Neurologist, Women's and Children's Hospital
Dr Chris Pearson General Medicine, Women's and Children's Hospital
Dr Ganessan Kichenadasse Consultant, Medical Oncology, Flinders Medical Centre
Dr Sudarsha  Selva-Nayagam Director Medical Oncology, Royal Adelaide Hospital
Dr Michael Ward Lecturer, School of Pharmacy and Medical Sciences, University of South Australia
Ms Joy Gailer Clinical Pharmacist, Drug and Therapeutics Information Service, Repatriation General Hospital
Ms Catherine Booth Clinical Pharmacist, Women's and Children's Hospital
Ms Kirsty Scarborough Senior Pharmacist, Royal Adelaide Hospital
Professor Tracy Merlin Manager, Adelaide Health technology Assessment, University of Adelaide
Dr Jennie Louise Senior Statistician and ethicist, Adelaide Health Technology Assessment
Dr Benjamin Reddi Staff Specialist, Intensive Care Unit, Royal Adelaide Hospital
Ms Naomi Burgess Director, Medicines & Technology Programs, SA Health (ex officio)
Dr Pravin Hissaria Clinical Immunologist and Immunopathologist, Royal Adelaide Hospital
Ms Anne Mussared Consumer representative, Health Consumers Alliance, South Australia
Ms Camille Schubert Health Economist, Adelaide Health technology Assessment, University of Adelaide
Dr Rami Tadros Department of Clinical Pharmacology, The Royal Adelaide Hospital, South Australia
Dr David Ross Department of Haematology and Bone Marrow Transplantation, The Royal Adelaide Hospital
Ms Laura Zanin,
Executive Office
Senior Pharmacist, Medicines & Technology Programs, SA Health


All enquiries regarding the High Cost Medicines policy or SAMEP should be directed to the Executive Officer to SAMEP at

^ Back to top